0001178913-17-001345.txt : 20170509 0001178913-17-001345.hdr.sgml : 20170509 20170509160749 ACCESSION NUMBER: 0001178913-17-001345 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20170509 FILED AS OF DATE: 20170509 DATE AS OF CHANGE: 20170509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Foamix Pharmaceuticals Ltd. CENTRAL INDEX KEY: 0001606645 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36621 FILM NUMBER: 17826436 BUSINESS ADDRESS: STREET 1: 2 HOLZMAN ST. STREET 2: WEIZMANN SCIENCE PARK CITY: REHOVOT STATE: L3 ZIP: 76704 BUSINESS PHONE: 97289316233 MAIL ADDRESS: STREET 1: 2 HOLZMAN ST. STREET 2: WEIZMANN SCIENCE PARK CITY: REHOVOT STATE: L3 ZIP: 76704 FORMER COMPANY: FORMER CONFORMED NAME: Foamix Ltd. DATE OF NAME CHANGE: 20140428 6-K 1 zk1719911.htm 6-K
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16
OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2017

Commission file number: 001-36621

FOAMIX PHARMACEUTICALS LTD.
(Translation of registrant's name into English)

2 Holzman Street, Weizmann Science Park
Rehovot, Israel
 (Address of principal executive office)
_____________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F S           Form 40-F £

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): £

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): £

 
CONTENTS

This report on Form 6-K of the registrant consists of a press release issued by the registrant on May 9, 2017, announcing the registrant’s first quarter financial results for the three months ended March 31, 2017, and including the registrant’s unaudited condensed consolidated balance sheets, statements of operations and statements of cash flows, attached hereto as an exhibit and incorporated by reference herein.

The information contained in this Form 6-K is incorporated by reference into (i) the registration statement on Form S-8 (number 333-199486) of the registrant, filed with the Securities and Exchange Commission (the “SEC”), as amended by the post-effective registration statement on Form S-8 POS filed February 5, 2016, (ii) the registration statement on Form S-8 (number 333-209403) of the registrant, filed with the SEC, and (iii) the registration statement on Form F-3 (333-216224) of the registrant, declared effective by the SEC on March 14, 2017, in each case to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

Exhibit

99.1
Press release: “Foamix Reports First Quarter 2017 Financial Results and Provides Business Update”

 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 
FOAMIX PHARMACEUTICALS LTD.
(Registrant)
  
       
 
By:
/s/Ilan Hadar
  
   
Name: Ilan Hadar
  
   
Title: Chief Financial Officer
  
       
Date: May 9, 2017

2
 EX-99.1 2 exhibit_99-1.htm EXHIBIT 99.1

Exhibit 99.1
 
 
News Release
 
 
May 9, 2017
 
Foamix Reports First Quarter 2017 Financial Results and Provides Business Update

Conference Call and Webcast on Wednesday, May 10, 2017 at 8:30am Eastern / 5:30am Pacific

Rehovot, Israel May 9, 2017 – Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix Pharmaceuticals” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today financial results for the three months ended March 31, 2017.

Clinical, business and corporate developments for the three months ended March 31, 2017 and to date:
 
·
On March 27, 2017, we provided the top-line data from our two Phase 3 clinical trials (Trial 04 and 05) for FMX101 in the treatment of moderate-to-severe acne. In the intent-to-treat analysis, FMX101 demonstrated statistical significance compared to vehicle on both co-primary endpoints in Trial 05 (specifically the absolute reduction in inflammatory lesions at week 12, and investigator global assessment (IGA) treatment success at week 12 compared to baseline). In Trial 04, statistical significance was demonstrated for FMX101 compared to vehicle in the co-primary endpoint of absolute reduction in inflammatory lesions, however, statistical significance was not achieved in the co-primary endpoint of IGA treatment success.
 
·
On May 3, 2017, we provided new data from our two Phase 3 clinical trials for FMX101, including pooled analysis of our co-primary endpoints and certain secondary clinical endpoints (absolute reduction of non-inflammatory lesions at week 12; and percent change in inflammatory lesions at weeks 3, 6, 9 and 12). Highlights from our further analyses included:
 
 
o
Statistical significance was demonstrated for FMX101 compared to vehicle in the pooled analysis of both co-primary endpoints – absolute reduction of inflammatory lesions and Investigator’s Global Assessment (IGA)
 
 
o
% Change in inflammatory lesion count was statistically significant in both Trials 04 and 05 at all timepoints (beginning at Week 3)
 
 
o
Non-inflammatory lesion count reduction at Week 12 was statistically significant in both Trials 04 and 05
 
 
o
Overall high level of patient satisfaction with FMX101 (based on patient satisfaction questionnaires).
 
 
o
FMX101 was generally safe and tolerable. No serious adverse events drug-related systemic side effects were recorded.
 
·
Further to sharing the detailed analyses, we announced that based on the results of the first two pivotal trials (Trial 04 and 05), we intend to conduct a third U.S. Phase 3 trial in patients with moderate-to-severe acne. This double-blind, vehicle-controlled trial is planned to enroll 1,500 patients who will be randomized 1:1 (FMX101 vs vehicle) across an estimated 80 investigator sites. The trial is expected to commence mid-year. If the results are positive, this trial will form the basis for a New Drug Application (NDA) which the company plans to submit in the second half of 2018.
 
·
The two Phase 3 clinical trials for FMX103 in patients with moderate-to-severe papulopustular rosacea are expected to commence mid-2017. We also announced on May 3, 2017, that we plan to increase the sample size for each of the two Phase 3 trials from 600 to 750 patients (total of 1,500 patients) randomized 2:1 (FMX103 vs vehicle) across an estimated 80 investigator sites in the U.S. FMX103 demonstrated clinically and statistically significant efficacy in treating moderate-to-severe rosacea in a Phase 2 trial which enrolled 233 patients across 18 sites in Germany.
 
·
During the first quarter of 2017 we successfully manufactured three registration-quality batches for FMX101.
 
·
U.S. Sales of Finacea® Foam, azelaic acid 15% for the treatment of rosacea, continue to grow.
 
 
o
Based on sales of Finacea® Foam reported by Bayer HealthCare AG for Q1, 2017 Foamix is entitled to royalty payments of $927,000, up 26% from the fourth quarter of 2016.
 
 
o
Finacea® Foam was developed through a research and development collaboration between Foamix and Bayer, utilizing Foamix's proprietary foam technology platform. The drug was launched by Bayer in the USA in September 2015.
 
Financial highlights for the three months ended March 31, 2017:
 
·
Total revenues were $927,000 compared with $745,000 for the three months ended March 31, 2016. The increase is due to increase in sales of Finacea® Foam by Bayer HealthCare AG.
 
·
Research and development expenses were $12.7 million, compared with $3.6 million in the three months ended March 31, 2016. This increase resulted primarily from an increase in costs relating to the FMX101 and FMX103 clinical trials as well as an increase in payroll and related expenses due to an increase in the number of R&D employees.
 
·
Selling, general and administrative expenses were $2.8 million, compared with $1.7 million in the three months ended March 31, 2016. The increase in selling, general and administrative expenses resulted primarily from increases in payroll and other payroll-related expenses, market research costs, advisors, maintenance and office expenses.
 
·
Operating expenses totaled $15.5 million, compared with $5.3 million in the three months ended March 31, 2016.
 
·
Net loss was $14.4 million or $0.39 per share, basic and diluted, compared with a loss of $4.5 million or $0.15 per share, basic and diluted, for the three months ended March 31, 2016.
 
·
Cash and investments as of March 31, 2017 totaled $118.7 million, compared with $131.0 million as of December 31, 2016.
 
Management overview

·
On March 27, 2017, we provided the top-line data from our two Phase 3 clinical trials (Trial 04 and 05) for FMX101 in the treatment of moderate-to-severe acne. In the intent-to-treat analysis, FMX101 demonstrated statistical significance compared to vehicle on both co-primary endpoints in Trial 05 (specifically the absolute reduction in inflammatory lesions at week 12, and investigator global assessment (IGA) treatment success at week 12 compared to baseline). In Trial 04, statistical significance was demonstrated for FMX101 compared to vehicle in the co-primary endpoint of absolute reduction in inflammatory lesions, however, statistical significance was not achieved in the co-primary endpoint of IGA treatment success. On May 3, 2017, we provided new data from our two Phase 3 clinical trials for FMX101, including pooled analysis of our co-primary endpoints and certain secondary clinical endpoints (absolute reduction of non-inflammatory lesions at week 12; and percent change in inflammatory lesions at weeks 3, 6, 9 and 12). Statistical significance was demonstrated for FMX101 compared to vehicle in the pooled analysis of the co-primary endpoints as well as the secondary endpoints presented.
 
Co-primary endpoint - Absolute change from baseline in inflammatory lesion count at week 12:
 
·
Trial 04: reduction of 14.16 lesions (or -14.16) for FMX101 and reduction of 11.17 lesions (or -11.17) for the vehicle (p<0.01)
 
·
Trial 05: -13.46 for FMX101 and -10.72 for vehicle (p<0.01)
 
·
Pooled Analysis: Absolute change in inflammatory lesion count was -13.79 for the FMX101, 4% treatment group and -10.94 for vehicle (p=0.0001)
 
Co-primary endpoint - Proportion of patients with Investigator's Global Assessment (IGA) success at week 12:
 
·
Trial 04:  IGA treatment success for FMX101, 4% treatment group was 8.09% versus 4.77% in vehicle (p=0.2178)
 
·
Trial 05: IGA treatment success for FMX101, 4% treatment group was 14.67% versus 7.89% in vehicle (p<0.05)
 
·
Pooled Analysis: IGA treatment success was 11.51% for FMX101, 4% treatment group and 6.34% for vehicle (p<0.05)
 
Secondary efficacy endpoint - Percent change from baseline in inflammatory lesion count at weeks 3, 6, 9 and 12:
 
·
Trial 04: reduction of 29% for FMX101 vs. reduction of 19% for vehicle, or -29% vs. -19%, at week 3 (p<.001); -37% vs. -26% at week 6 (p<.001); -42% vs. -28% at week 9 (p<.0001); and -44% vs. -34% at week 12 (p<0.01)
 
·
Trial 05: reduction of 34% for FMX101 vs. reduction of 21% for vehicle, or -34% vs. -21%, at week 3 (p<.0001); -39% vs. -27% at week 6 (p<.0001); -43% vs. -31% at week 9 (p<.001); and: -43% vs. -34% at week 12 (p<0.01)
 
Secondary efficacy endpoint – Absolute change from baseline in non-inflammatory lesion count at week 12:
 
·
Trial 04: reduction of 16.45 lesions (or -16.45) for the FMX101, 4% treatment group and reduction of 10.30 lesions (or -10.30) for the vehicle (p<0.01)
 
·
Trial 05: reduction of 13.20 (or -13.20) for the FMX101, 4% treatment group and reduction of 7.00 (or -7.00) for the vehicle (p<0.05)
 
·
Pooled Analysis: Absolute change in non-inflammatory lesion count was -14.76 for the FMX101, 4% treatment group and -8.64 for vehicle (p<0.01)
 
·
As we announced on May 3, 2017, based on the results of the first two pivotal trials (Studies 04 and 05), the company intends to conduct a third U.S. Phase 3 trial in patients with moderate-to-severe acne.  If the results are positive, this trial will form the basis for an NDA which the company plans to submit in the second half of 2018.  This planned clinical trial will be conducted at approximately 80 investigator sites in the U.S.  In order to achieve the necessary statistical power compared with the prior Phase 3 trials, the target patient enrollment number has been increased to 1,500.  Patients will be randomized 1:1 to receive either FMX101 (minocycline foam 4%) or vehicle foam once daily over 12 weeks. The co-primary efficacy endpoints will be identical to the prior Phase 3 trials: (1) mean change from baseline in the inflammatory lesion count, and (2) proportion of patients with IGA scores of “Clear” or “Almost Clear”, with improvement of at least two grades from baseline. The inclusion criteria will be consistent with the prior Phase 3 trials.
 
·
We intend to meet with the FDA to review the results of our Phase 3 clinical trials for FMX101 (Trial 04 and 05) and our third Phase 3 trial, which we expect to commence mid-year.
 
·
Following the results of the first two pivotal trials for FMX101 in moderate-to-severe acne, we have also reviewed our Phase 3 program for FMX103 in papulopustular rosacea, which is expected to commence around mid-2017.  Based on the outcome of the Phase 3 studies for FMX101, and the planned increase in the number of patients to be enrolled in the third Phase 3 trial in acne, we also intend to increase the sample size for the two planned Phase 3 studies for FMX103 in papulopustular rosacea.  The sample size will be increased from 600 patients per trial to 750 patients per trial, for a total of 1,500 patients across the two studies.
 
·
Regarding manufacturing, we have successfully completed the scale-up process for FMX101 to a commercial batch size of one-ton. The production of three registration batches has been completed.
 
·
In addition to our internal drug development pipeline, we have development and license agreements relating to our proprietary foam technology with other pharmaceutical companies, including Bayer Healthcare and others, in various stages of development and commercialization. Our agreements with these licensees entitle us to development fees, contingent payments and royalties upon commercialization.
 
·
In September 2015, Bayer Healthcare began selling Finacea® Foam (azelaic acid 15% for the treatment of rosacea) in the U.S.  Finacea® foam is a prescription foam product which was developed as part of a research and development collaboration between Foamix and Bayer, utilizing Foamix's proprietary foam technology platform.  According to our license agreement with Bayer, we are entitled to royalties upon commercialization of Finacea Foam.  For the three months ended March 31, 2017, we were entitled to royalties from Bayer in an amount of $927,000, up 26% from the fourth quarter of 2016.
 
·
The Company is currently well-capitalized and has sufficient cash to fund our key development programs (FMX101 and FMX103) through NDA registration.
 
Financial results for the three months ended March 31, 2017
 
Revenues
Total revenues for the three-month ended March 31, 2017 were $927,000 compared with $745,000 for the three months ended March 31, 2016. The increase is due to increase in sales of Finacea® Foam by Bayer HealthCare AG.

Operating Expenses
Our operating expenses for the three months ended March 31, 2017, and three months ended March 31, 2016, were as follows:

Research and Development Expenses
Research and development expenses increased by $9.1 million, or 253%, from $3.6 million in the three months ended March 31, 2016, to $12.7 million in the three months ended March 31, 2017. The increase in research and development expenses resulted primarily from an increase of $7.9 million in costs relating to the FMX101 and FMX103 clinical trials and an increase of $1.1 million in payroll and payroll related expenses (including bonuses and equity-based compensation) due to an increase in the number of R&D employees.

Selling, General and Administrative Expenses
Selling, general and administrative expenses increased by $1.1 million, or 65%, from $1.7 million in the three months ended March 31, 2016, to $2.8 million in the three months ended March 31, 2017. The increase in selling, general and administrative expenses resulted primarily from an increase of $300,000 in payroll and other payroll-related expenses (including bonuses and equity-based compensation), an increase of $250,000 in advisors, consultants and other professional services, $102,000 in market research costs and $122,000 in rent, maintenance and office expenses.

Finance Income, Net
For the three months ended March 31, 2017, we recorded financial income of $257,000 compared to financial income of $174,000 recorded for the three months ended March 31, 2016. The financial income for the three months ended March 31, 2017 and 2016 resulted mostly from interest and financial gains from our cash investments.

Net Loss
For the three months ended March 31, 2017, we recorded a loss of $14.4 million or $0.39 per share, basic and diluted, compared with a loss of $4.5 million or $0.15 per share, basic and diluted, for the three months ended March 31, 2016.

Liquidity and Capital Resources
As of March 31, 2017, we had cash and investments of $118.7 million, compared with $131.0 million as of December 31, 2016. The decrease was mostly due to operating expenses primarily relating to the clinical trials. During the three months ended March 31, 2017 we used $12.1 million in cash in our operations compared to $7.0 million used in operating activities in the three months ended March 31, 2016.

Conference Call
Management will host an investment community conference call on May 10, 2017 at 8:30 a.m. Eastern / 5:30 a.m. Pacific / 3:30 p.m. Israel to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing Domestic: 888-438-5519; International: +1-719-457-1506. Conference ID: 2254081.  Webcast: http://public.viavid.com/index.php?id=124151

A replay of the call will be accessible two hours after its completion through May 24, 2017 by dialing Domestic: 844-512-2921; International: +1-412-317-6671; Passcode: 2254081. The call will also be archived for 90 days at www.streetevents.com and www.foamixpharma.com.

About Foamix
Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX102 for the treatment of impetigo, FMX103 for the treatment of rosacea and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs.

In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare and others.
 
Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions, expectations, forecasts, beliefs or intentions related to financial results, commercial results, timing and results of clinical trials and U.S. FDA and other regulatory agencies authorizations. Forward-looking statements are based on our current knowledge and our present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of various factors including, but not limited to, unexpected delays, excess costs or unfavorable results of clinical trials, delays or denial in the U.S. FDA approval process, additional competition in the acne market, denial of reimbursement by third party payors or inability to raise additional capital. We discuss many of these risks in greater detail under the heading “Risk Factors” in our most recent Annual Report on Form 20-F (File No. 17625089) filed on February 21, 2017, and elsewhere in that Annual Report. Although we believe these forward-looking statements are reasonable, they speak only as of the date of this announcement and Foamix undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law. Given these risks and uncertainties, you should not rely upon forward-looking statements as predictions of future events.

Finacea® is a registered trademark of Bayer Healthcare.
 
Contact:
U.S. Investor Relations
Ilan Hadar, CFO
Michael Rice
Foamix Pharmaceuticals Ltd.
LifeSci Advisors, LLC
+972-8-9316233
646-597-6979
ilan.hadar@foamixpharma.com
mrice@lifesciadvisors.com

FOAMIX PHARMACEUTICALS LTD.
CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands, except per share data)
(Unaudited)
 
   
March 31,
    
December 31,
  
   
2017
    
2016
  
A s s e t s
      
CURRENT ASSETS:
      
Cash and cash equivalents
  
$
26,157
    
$
31,190
  
Restricted cash
    
250
      
250
  
Short term bank deposits
    
38,488
      
38,351
  
Investment in marketable securities
    
35,875
      
43,275
  
Restricted investment in marketable securities
    
276
      
261
  
Accounts receivable:
                
Trade
    
2,413
      
3,236
  
Other
    
1,718
      
438
  
TOTAL CURRENT ASSETS
    
105,177
      
117,001
  
                 
NON-CURRENT ASSETS:
                
Investment in marketable securities
    
17,529
      
17,532
  
Restricted investment in marketable securities
    
137
      
129
  
Property and equipment, net
    
1,084
      
938
  
Other
    
35
      
35
  
TOTAL NON-CURRENT ASSETS
    
18,785
      
18,634
  
                 
TOTAL ASSETS
  
$
123,962
    
$
135,635
  
 
FOAMIX PHARMACEUTICALS LTD.
CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands, except per share data)
(Unaudited)

   
March 31,
    
December 31,
  
   
2017
    
2016
  
Liabilities and shareholders’ equity
            
CURRENT LIABILITIES:
            
Current maturities of bank borrowing
  
$
13
    
$
20
  
Accounts payable and accruals:
                
Trade
    
5,061
      
2,267
  
     Other
    
1,873
      
2,984
  
TOTAL CURRENT LIABILITIES
    
6,947
      
5,271
  
                 
LONG-TERM LIABILITIES:
                
Liability for employee severance benefits
    
470
      
379
  
TOTAL LONG-TERM LIABILITIES
    
470
      
379
  
TOTAL LIABILITIES
    
7,417
      
5,650
  
COMMITMENTS
                
SHAREHOLDERS' EQUITY:
                
Ordinary Shares, NIS 0.16 par value - authorized: 50,000,000 Ordinary Shares as of March 31, 2017
     and December 31, 2016; issued and outstanding: 37,223,485 and 37,167,791 Ordinary Shares
     as of March 31, 2017 and December 31, 2016, respectively
    
1,564
      
1,561
  
Additional paid-in capital
    
204,952
      
204,052
  
Accumulated deficit
    
(89,950
)
    
(75,566
)
Accumulated other comprehensive loss
    
(21
)
    
(62
)
TOTAL SHAREHOLDERS' EQUITY
    
116,545
      
129,985
  
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY
  
$
123,962
    
$
135,635
  

 
FOAMIX PHARMACEUTICALS LTD.
CONSOLIDATED STATEMENTS OF OPERATIONS
 (U.S. dollars in thousands, except per share data)
(Unaudited)

   
Three months ended
  
   
March 31,
  
   
2017
    
2016
  
REVENUES
  
$
927
    
$
745
  
COST OF REVENUES
    
-
      
31
  
GROSS PROFIT
    
927
      
714
  
OPERATING EXPENSES:
                
Research and development
    
12,675
      
3,566
  
Selling, general and administrative
    
2,822
      
1,710
  
TOTAL OPERATING EXPENSES
    
15,497
      
5,276
  
OPERATING LOSS
    
14,570
      
4,562
  
FINANCE INCOME, net
    
(257
)
    
(174
)
LOSS BEFORE INCOME TAX
    
14,313
      
4,388
  
INCOME TAX
    
71
      
120
  
NET LOSS FOR THE PERIOD
  
$
14,384
    
$
4,508
  
                 
LOSS PER SHARE BASIC AND DILUTED
  
$
0.39
    
$
0.15
  
                 
WEIGHTED AVERAGE NUMBER OF SHARES
    OUTSTANDING USED IN COMPUTATION
    OF BASIC AND DILUTED LOSS PER SHARE IN THOUSANDS
    
37,188
      
30,654
  

FOAMIX PHARMACEUTICALS LTD.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
 (U.S. dollars in thousands)
(Unaudited)

   
Three months ended
  
   
March 31,
  
   
2017
    
2016
  
NET LOSS
            
OTHER COMPREHENSIVE INCOME:
  
$
14,384
    
$
4,508
  
Net unrealized gains from marketable securities
    
(6
)
    
(156
)
Gains on marketable securities reclassified into net loss
    
-
      
2
  
Net unrealized gains on derivative financial instruments
    
(75
)
    
(78
)
Gains on derivative financial instruments reclassified into net loss
    
40
      
4
  
TOTAL OTHER COMPREHENSIVE INCOME
    
(41
)
    
(228
)
TOTAL COMPREHENSIVE LOSS
  
$
14,343
    
$
4,280
  
 
FOAMIX PHARMACEUTICALS LTD.
CONSOLIDATED STATEMENTS OF CASH FLOWS
 (U.S. dollars in thousands)
(Unaudited)
 
   
Three months ended
  
   
March 31,
  
   
2017
    
2016
  
CASH FLOWS FROM OPERATING ACTIVITIES:
            
Net Loss
  
$
(14,384
)
  
$
(4,508
)
Adjustments required to reconcile net loss to net cash used in operating activities:
                
Depreciation and amortization
    
44
      
30
  
Loss from disposal of fixed assets
    
102
       -  
Changes in marketable securities and bank deposits, net
    
96
      
(2
)
Changes in accrued liability for employee severance benefits, net of retirement fund profit
    
91
      
22
  
Share-based compensation
    
766
      
533
  
Non-cash finance expenses (income), net
    
(47
)
    
2
  
Changes in operating asset and liabilities:
                
Increase in trade and other receivable
    
(392
)
    
(2,346
)
Increase (decrease) in accounts payable and accruals
    
1,671
      
(759
)
Net cash used in operating activities
    
(12,053
)
    
(7,028
)
CASH FLOWS FROM INVESTING ACTIVITIES:
                
Purchase of fixed assets
    
(280
)
    
(115
)
Investment in bank deposits
    
(13,207
)
    
(13,000
)
Investment in marketable securities
    
(2,913
)
    
(700
)
Proceeds from sale and maturity of marketable securities and bank deposits
    
23,273
      
21,149
  
Net cash provided by investing activities
    
6,873
      
7,334
  
CASH FLOWS FROM FINANCING ACTIVITIES:
                
Proceeds from exercise of options
    
137
      
-
  
Payments in respect of bank borrowings
    
(8
)
    
(8
)
Net cash provided by financing activities
    
129
      
(8
)
INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH
    
(5,051
)
    
298
  
EFFECT OF EXCHANGE RATE ON CASH, CASH EQUIVALENTS AND RESTRICTED CASH
    
18
      
9
  
CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF THE PERIOD
    
31,440
      
18,795
  
CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF THE PERIOD
  
$
26,407
    
$
19,102
  
Cash and cash equivalents
  
$
26,157
    
$
19,102
  
Restricted cash
    
250
      
-
  
TOTAL CASH, CASH EQUIVALENTS AND RESTRICTED CASH SHOWN IN STATEMENT OF CASH FLOWS
  
$
26,407
    
$
19,102
  
SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS -
                
Property and equipment purchases included in accounts payable and accruals
  
$
39
    
$
-
  
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
                
Cash paid for taxes
  
$
-
    
$
91
  
Interest received
  
$
178
    
$
-
  
Interest paid
  
$
*-
    
$
*-
  

* Represents an amount less than $1.


 GRAPHIC 3 image2.jpg begin 644 image2.jpg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end